revealed that all mutated proteins showed no enzymatic activity except for ChOAS-L-AΔUbL2.
cells/dish for 24 h, the cells were transfected with 10 µg of pIRES-EGFP (empty vector as a The protein concentrations were determined using SmartSpec TM (BioRad) according to the blocked with PBS containing 3% non-fatty milk and 0.1% Tween-20 for 1 h at room temperature. The enzymatic activity of ChOAS-L-A protein and all of its mutants was measured as stopped by boiling for 5 min at 95 °C, followed by adding loading buffer containing 25% 18 formamide, 0.5% bromophenol blue, and 0.5% xylene cyanol.
19
The synthetized 2'-5' (A) products were run in a 20% polyacrylamide-urea (7 M) gel. The 20 electrophoresis was performed for 4 h on 200 V, and then products were visualized by 21 autoradiography with a BAS2500 Bio-Imaging analyzer (FUJIFILM, Tokyo, Japan). The protein stability assay was performed by incubating the protein samples (12 µg) in the presence or absence of protease inhibitors at 37°C for 2 h. The incubated samples were subjected to Austin, TX, USA) according to manufacturer's protocol. Concentration of purified total RNA 18 samples were determined using SmartSpec TM (BioRad), 1 µg of total RNA was used to generate 19 cDNAs using ReverTra Ace ® (Toyobo Co., Ltd. Osaka, Japan) according to manufacturer's protocol.
20
The RT condition was at 42° C for 60 min and at 99 °C for 5 min. The synthesized cDNA was 21 stored at -20°C until used for the PCR, of which conditions were as follow; denature at 95 °C for 5 22 min; 35 cycles of denature at 95 °C for 30 sec, annealing at 60 °C for 30 sec, and extension at 72 °C 23 for 1.5 min; followed by the final extension at 72 °C for 3 min. The RNase-L activation assay for ChOAS-L-A protein and all of its mutated proteins was 21 performed using the florescence resonance energy transfer assay (FRET assay) as described or ΔLxxxP (Fig. 3B) . Although ΔUbL1/UbL2 showed antiviral activity, its extent was partial when 19 compared to that of ChOAS-L-A, suggesting that UbL domain is necessary for the antiviral activity.
However, the result that ChOAS-L-B, partial deletion of UbL1, and ΔUbL2 showed almost full 21 antiviral activity suggest that a single copy of UbL domain is satisfactory to retain the antiviral 22 activity.
23
The same trend was seen in the BALB/3T3 cells, all mutants significantly (p<0.01) showed 24 antiviral activity to reduce the SEAP activity compared with control groups. Moreover, the Therefore, in the current study, eight ChOAS-L-A mutants were generated by using site-directed 25 mutagenesis protocol or ordinary PCR protocol, in which five mutations were introduced in the domains of the OAS unit and the other three mutations were in the UbL domains, to investigate the incubated in the lysis buffer in the absence of the proteases inhibitors (Fig. 5) UbL domain is enough for ChOAS-L-A protein to express the enzymatic activity (Fig 2-B) .
showed incapability to activate RNase L in FRET assay, and expresses the same level as the 7 negative control (Fig. 6) , and localized into cytoplasm as well as the wild type ChOAS-L-A protein 8 (Fig. 7) . ChOAS-L-A-ΔUbL1/UbL2, is for sure due to the OAS/RNase L independent pathway.
5
In conclusion, the obtained results suggest that the ChOAS-L expresses the antiviral activity in a 6 manner independent of the OAS/RNase L classical pathway. However, it may be premature to state ChOAS-L functions without investigating other avian OAS family members for enzymatic and 8 antiviral activities not only against WNV but against specific avian pathogens.
9 Table 1 . Primers used to generate mutations from the wild-typed ChOAS-L-A gene and primers for 1 EGFP and Actb genes. 
